Literature DB >> 16079041

Narcolepsy-cataplexy: how does recent understanding help in evaluation and treatment.

Mujahid Mahmood1, Jed Black.   

Abstract

Narcolepsy is a substantially disabling disease with profound physical, mental, and social effects. The burden on patients is compounded by delayed and missed diagnoses and by the subsequent undertreatment of narcolepsy and associated symptoms such as cataplexy. The recent advances in the elucidation of the genetics of canine narcolepsy and the pathophysiologic role of hypocretin, in animals and humans, enhances current diagnostic capability and will provide better treatment modalities in the future. The varied symptoms of narcolepsy are challenging to manage and may require treatment with a combination of agents. The recent development of a markedly enhanced characterization of sodium oxybate in the treatment of the excessive daytime sleepiness, nocturnal sleep fragmentation, and cataplexy of narcolepsy offers the potential of treating multiple symptoms simultaneously and marks a dramatic advance in the treatment of narcolepsy.

Entities:  

Year:  2005        PMID: 16079041     DOI: 10.1007/s11940-005-0029-8

Source DB:  PubMed          Journal:  Curr Treat Options Neurol        ISSN: 1092-8480            Impact factor:   3.972


  19 in total

1.  Orally administered sodium oxybate for the treatment of narcolepsy.

Authors:  Michael Thorpy
Journal:  Curr Neurol Neurosci Rep       Date:  2004-03       Impact factor: 5.081

Review 2.  Clinical aspects and features of cataplexy.

Authors:  C Guilleminault; M Gelb
Journal:  Adv Neurol       Date:  1995

3.  Hypocretin (orexin) deficiency in human narcolepsy.

Authors:  S Nishino; B Ripley; S Overeem; G J Lammers; E Mignot
Journal:  Lancet       Date:  2000-01-01       Impact factor: 79.321

Review 4.  Genetic and familial aspects of narcolepsy.

Authors:  E Mignot
Journal:  Neurology       Date:  1998-02       Impact factor: 9.910

5.  A 12-month, open-label, multicenter extension trial of orally administered sodium oxybate for the treatment of narcolepsy.

Authors: 
Journal:  Sleep       Date:  2003-02-01       Impact factor: 5.849

6.  Sleep onset REM periods during multiple sleep latency tests in patients evaluated for sleep apnea.

Authors:  R D Chervin; M S Aldrich
Journal:  Am J Respir Crit Care Med       Date:  2000-02       Impact factor: 21.405

Review 7.  Narcolepsy.

Authors:  Ann E Rogers; H Michael Dreher
Journal:  Nurs Clin North Am       Date:  2002-12       Impact factor: 1.208

8.  A pilot study on the effects of sodium oxybate on sleep architecture and daytime alertness in narcolepsy.

Authors:  Mortimer Mamelak; Jed Black; Jacques Montplaisir; Ruzica Ristanovic
Journal:  Sleep       Date:  2004-11-01       Impact factor: 5.849

Review 9.  Sodium oxybate for the treatment of narcolepsy.

Authors:  Michael J Thorpy
Journal:  Expert Opin Pharmacother       Date:  2005-02       Impact factor: 3.889

10.  Daytime sleepiness, snoring, and obstructive sleep apnea. The Epworth Sleepiness Scale.

Authors:  M W Johns
Journal:  Chest       Date:  1993-01       Impact factor: 9.410

View more
  1 in total

Review 1.  Disrupted nighttime sleep in narcolepsy.

Authors:  Thomas Roth; Yves Dauvilliers; Emmanuel Mignot; Jacques Montplaisir; Josh Paul; Todd Swick; Phyllis Zee
Journal:  J Clin Sleep Med       Date:  2013-09-15       Impact factor: 4.062

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.